sur ABIONYX (EPA:ABNX)
ABIONYX Successfully Completes €3.4 Million Capital Increase
ABIONYX Pharma has conducted a successful capital increase, raising approximately €3.4 million. This increase was achieved through the issue of 2,472,000 new shares, each accompanied by a warrant. The subscription price was set at €1.37 per share with a warrant.
Each warrant allows the holder to subscribe for a new share at a price of €3, with an exercise period of three years. This fundraising aims to bolster the company's cash position and support its development efforts, particularly in sepsis and the U.S. market.
The shares issued will constitute about 7.62% of the current share capital. These shares carry dividend rights and are assimilated to existing shares, trading on Euronext. The operation, authorized by the Board of Directors, does not require an AMF-approved prospectus.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIONYX